Human mesenchymal stromal/stem cells acquire immunostimulatory capacity upon cross-talk with natural killer cells and might improve the NK cell function of immunocompromised patients

Stem Cell Research and Therapy

Volumn 7, Issue 1, 2016, Pages

  Cui, Rongtao ^a   Rekasi, Heike ^a   Hepner Schefczyk, Monika ^a   Fessmann, Kai ^a   Petri, Robert M ^a   Bruderek, Kirsten ^a   Brandau, Sven ^a   Jäger, Marcus ^a   Flohé, Stefanie B ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

CCL2; CCR2; Chemokines; Immunosuppression; Injury; Interferon gamma; MCP 1; Mesenchymal stem cells; Mesenchymal stromal cells; Natural killer cells; Trauma

Indexed keywords

CHEMOKINE RECEPTOR CCR2; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 12; INTERLEUKIN 18; MONOCYTE CHEMOTACTIC PROTEIN 1; ANTIBODY; CCL2 PROTEIN, HUMAN; CCR2 PROTEIN, HUMAN; CONDITIONED MEDIUM; INTERFERON RECEPTOR; INTERLEUKIN 18 PROTEIN, HUMAN;

ADULT; ARTICLE; BONE MARROW; CELL ISOLATION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEEDBACK SYSTEM; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCOMPROMISED PATIENT; IMMUNOSTIMULATION; LYMPHOCYTE FUNCTION; MALE; MESENCHYMAL STEM CELL; MESENCHYMAL STROMA CELL; MOLECULAR INTERACTION; MONONUCLEAR CELL; NATURAL KILLER CELL; NOSE MUCOSA; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; CELL COMMUNICATION; CONDITIONED MEDIUM; CYTOLOGY; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; INJURY SCALE; MIDDLE AGED; MULTIPLE TRAUMA; PATHOLOGY; PHARMACOLOGY;

ADULT; ANTIBODIES; CELL COMMUNICATION; CHEMOKINE CCL2; COCULTURE TECHNIQUES; CULTURE MEDIA, CONDITIONED; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOMODULATION; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-18; KILLER CELLS, NATURAL; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; MULTIPLE TRAUMA; RECEPTORS, CCR2; RECEPTORS, INTERFERON; TRAUMA SEVERITY INDICES;

EID: 84978518690     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/s13287-016-0353-9     Document Type: Article

References (40)

1. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-7.
2. Yousefi AM, James PF, Akbarzadeh R, Subramanian A, Flavin C, Oudadesse H. Prospect of stem cells in bone tissue engineering: a review. Stem Cells Int. 2016;2016:6180487.
3. Chen L, Tredget EE, Wu PY, Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One. 2008;3:e1886.
4. Schepers K, Campbell TB, Passegue E. Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell. 2015;16:254-67.
5. Shi Y, Su J, Roberts AI, Shou P, Rabson AB, Ren G. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol. 2012;33:136-43.
6. English K. Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol. 2013;91:19-26.
7. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13:392-402.
8. Caligiuri MA. Human natural killer cells. Blood. 2008;112:461-9.
9. Lodoen MB, Lanier LL. Natural killer cells as an initial defense against pathogens. Curr Opin Immunol. 2006;18:391-8.
10. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008;111:1327-33.
11. Thomas H, Jäger M, Mauel K, Brandau S, Lask S, Flohé SB. Interaction with mesenchymal stem cells provokes natural killer cells for enhanced IL-12/IL-18-induced interferon-gamma secretion. Mediators Inflamm. 2014;2014:143463.
12. Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M. Immunosuppression following surgical and traumatic injury. Surg Today. 2010;40:793-808.
13. Jakob M, Hemeda H, Janeschik S, Bootz F, Rotter N, Lang S, et al. Human nasal mucosa contains tissue-resident immunologically responsive mesenchymal stromal cells. Stem Cells Dev. 2010;19:635-44.
14. hi NK cells as novel players in immunosuppression after polytrauma: impaired responsiveness to IL-12 causes deficits in the response to Staphylococcus aureus. Shock. 2015;44 Suppl 2:23.
15. Reinhardt R, Pohlmann S, Kleinertz H, Hepner-Schefczyk M, Paul A, Flohé SB. Invasive surgery impairs the regulatory function of human CD56bright natural killer cells in response to Staphylococcus aureus. Suppression of interferon-gamma synthesis. PLoS One. 2015;10:e0130155.
16. Brandau S, Jakob M, Bruderek K, Bootz F, Giebel B, Radtke S, et al. Mesenchymal stem cells augment the anti-bacterial activity of neutrophil granulocytes. PLoS One. 2014;9:e106903.
17. Evans JF, Salvador V, George S, Trevino-Gutierrez C, Nunez C. Mouse aorta-derived mesenchymal progenitor cells contribute to and enhance the immune response of macrophage cells under inflammatory conditions. Stem Cell Res Ther. 2015;6:56.
18. Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126:458-65.
19. Xu X, Wang Q, Deng B, Wang H, Dong Z, Qu X, et al. Monocyte chemoattractant protein-1 secreted by decidual stromal cells inhibits NK cells cytotoxicity by up-regulating expression of SOCS3. PLoS One. 2012;7:e41869.
20. Ren G, Zhao X, Wang Y, Zhang X, Chen X, Xu C, et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFalpha. Cell Stem Cell. 2012;11:812-24.
21. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008;2:141-50.
22. Rafei M, Hsieh J, Fortier S, Li M, Yuan S, Birman E, et al. Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood. 2008;112:4991-8.
23. Rafei M, Campeau PM, Aguilar-Mahecha A, Buchanan M, Williams P, Birman E, et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol. 2009;182:5994-6002.
24. Morandi F, Ferretti E, Castriconi R, Dondero A, Petretto A, Bottino C, et al. Soluble HLA-G dampens CD94/NKG2A expression and function and differentially modulates chemotaxis and cytokine and chemokine secretion in CD56bright and CD56dim NK cells. Blood. 2011;118:5840-50.
25. Maghazachi AA, Al-Aoukaty A, Schall TJ. C-C chemokines induce the chemotaxis of NK and IL-2-activated NK cells. Role for G proteins. J Immunol. 1994;153:4969-77.
26. Chatterjee D, Marquardt N, Tufa DM, Hatlapatka T, Hass R, Kasper C, et al. Human umbilical cord-derived mesenchymal stem cells utilize activin-A to suppress interferon-gamma production by natural killer cells. Front Immunol. 2014;5:662.
27. He YY, He XJ, Guo PF, Du MR, Shao J, Li MQ, et al. The decidual stromal cells-secreted CCL2 induces and maintains decidual leukocytes into Th2 bias in human early pregnancy. Clin Immunol. 2012;145:161-73.
28. Yu J, Wei M, Becknell B, Trotta R, Liu S, Boyd Z, et al. Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells. Immunity. 2006;24:575-90.
29. Townsend MJ, Weinmann AS, Matsuda JL, Salomon R, Farnham PJ, Biron CA, et al. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity. 2004;20:477-94.
30. Yamamoto K, Yamaguchi M, Miyasaka N, Miura O. SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor beta2 subunit. Biochem Biophys Res Commun. 2003;310:1188-93.
31. DelaRosa O, Lombardo E, Beraza A, Mancheno-Corvo P, Ramirez C, Menta R, et al. Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng Part A. 2009;15:2795-806.
32. Zhao X, Liu D, Gong W, Zhao G, Liu L, Yang L, et al. The toll-like receptor 3 ligand, poly(I:C), improves immunosuppressive function and therapeutic effect of mesenchymal stem cells on sepsis via inhibiting MiR-143. Stem Cells. 2014;32:521-33.
33. Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, Koppel A, et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells. 2009;27:909-19.
34. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24:386-98.
35. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762-74.
36. Akira S. The role of IL-18 in innate immunity. Curr Opin Immunol. 2000;12:59-63.
37. Trinchieri G. Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol. 1998;16:365-96.
38. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol. 2004;5:1260-5.
39. Duijvestein M, Vos AC, Roelofs H, Wildenberg ME, Wendrich BB, Verspaget HW, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut. 2010;59:1662-9.
40. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439-41.